HK1256307A1 - 用小分子混合物將人神經膠質細胞化學重編程為神經元 - Google Patents
用小分子混合物將人神經膠質細胞化學重編程為神經元Info
- Publication number
- HK1256307A1 HK1256307A1 HK18115373.5A HK18115373A HK1256307A1 HK 1256307 A1 HK1256307 A1 HK 1256307A1 HK 18115373 A HK18115373 A HK 18115373A HK 1256307 A1 HK1256307 A1 HK 1256307A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- neurons
- small molecule
- glial cells
- human glial
- chemical reprogramming
- Prior art date
Links
- 210000004498 neuroglial cell Anatomy 0.000 title 1
- 210000002569 neuron Anatomy 0.000 title 1
- 230000008672 reprogramming Effects 0.000 title 1
- 150000003384 small molecules Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0619—Neurons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/02—Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/42—Notch; Delta; Jagged; Serrate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases [EC 2.]
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/73—Hydrolases (EC 3.)
- C12N2501/734—Proteases (EC 3.4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/08—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from cells of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562263353P | 2015-12-04 | 2015-12-04 | |
PCT/US2016/064553 WO2017096123A1 (en) | 2015-12-04 | 2016-12-02 | Chemical reprogramming of human glial cells into neurons with small molecule cocktail |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1256307A1 true HK1256307A1 (zh) | 2019-09-20 |
Family
ID=58797771
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18115373.5A HK1256307A1 (zh) | 2015-12-04 | 2018-11-30 | 用小分子混合物將人神經膠質細胞化學重編程為神經元 |
Country Status (10)
Country | Link |
---|---|
US (2) | US9885015B2 (zh) |
EP (2) | EP3795147B1 (zh) |
JP (1) | JP6951336B2 (zh) |
KR (2) | KR102444438B1 (zh) |
CN (2) | CN108430582B (zh) |
AU (1) | AU2016364845B2 (zh) |
CA (1) | CA3007116A1 (zh) |
HK (1) | HK1256307A1 (zh) |
SG (1) | SG11201804440XA (zh) |
WO (1) | WO2017096123A1 (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT201800001168A1 (it) * | 2018-01-17 | 2019-07-17 | Fond Per Listituto Oncologico Di Ricerca Ior | Nuovi farmaci senolitici inibitori alk |
AU2020257262A1 (en) * | 2019-04-18 | 2021-11-18 | Brown University | Neurogenesis |
EP4065091A4 (en) * | 2019-11-25 | 2023-11-29 | The Penn State Research Foundation | COMPOSITION AND METHOD FOR CONVERTING HUMAN GLIA CELLS INTO NEURONS |
WO2021195706A1 (en) * | 2020-03-31 | 2021-10-07 | Children's Medical Research Institute | New dynamin inhibitors and uses |
WO2022095057A1 (zh) * | 2020-11-09 | 2022-05-12 | 深圳先进技术研究院 | 一种医药组合物及其医药用途 |
CN113244236B (zh) * | 2021-06-01 | 2023-02-03 | 上海市第一人民医院 | 色瑞替尼在制备治疗甲状腺相关眼病的药物中的应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2379149A1 (en) | 1999-07-09 | 2001-01-18 | Ortho-Mcneil Pharmaceutical, Inc. | Neurotrophic pyrrolidines and piperidines, and related compositions and methods |
GB0316882D0 (en) * | 2003-07-18 | 2003-08-20 | Consejo Superior Investigacion | Reversible immortalization of OEG from human olfactory bulbs as a tool to promote spinal cord regeneration |
JP2009538279A (ja) | 2006-03-09 | 2009-11-05 | ユニバーシティー オブ ロチェスター | 末梢および神経の炎症性クロストーク |
CN101732255A (zh) | 2010-01-07 | 2010-06-16 | 同济大学 | 一种氟比洛芬脂质体及其制备方法 |
EP2577318B1 (en) | 2010-05-25 | 2019-06-26 | Memorial Sloan-Kettering Cancer Center | Method of nociceptor differentiantion of human embryonic stem cells and uses thereof |
CN114601937A (zh) * | 2012-07-19 | 2022-06-10 | 宾夕法尼亚州研究基金会 | 再生用于在神经系统中治疗疾病和损伤的功能性神经元 |
EP3881857A1 (en) * | 2016-02-18 | 2021-09-22 | The Penn State Research Foundation | Generating gabaergic neurons in brains |
WO2020263639A1 (en) * | 2019-06-28 | 2020-12-30 | The Penn State Research Foundation | Methods and materials for treating huntington's disease |
-
2016
- 2016-12-02 US US15/367,382 patent/US9885015B2/en active Active
- 2016-12-02 WO PCT/US2016/064553 patent/WO2017096123A1/en active Application Filing
- 2016-12-02 CN CN201680077502.1A patent/CN108430582B/zh active Active
- 2016-12-02 CN CN202010064422.0A patent/CN111184739B/zh active Active
- 2016-12-02 KR KR1020207010846A patent/KR102444438B1/ko active IP Right Grant
- 2016-12-02 CA CA3007116A patent/CA3007116A1/en active Pending
- 2016-12-02 EP EP20207658.4A patent/EP3795147B1/en active Active
- 2016-12-02 KR KR1020187019038A patent/KR102102837B1/ko active IP Right Grant
- 2016-12-02 JP JP2018527791A patent/JP6951336B2/ja active Active
- 2016-12-02 SG SG11201804440XA patent/SG11201804440XA/en unknown
- 2016-12-02 AU AU2016364845A patent/AU2016364845B2/en active Active
- 2016-12-02 EP EP16871554.8A patent/EP3383495B1/en active Active
-
2017
- 2017-12-01 US US15/828,652 patent/US10253293B2/en active Active
-
2018
- 2018-11-30 HK HK18115373.5A patent/HK1256307A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
SG11201804440XA (en) | 2018-06-28 |
KR102102837B1 (ko) | 2020-04-22 |
CN111184739B (zh) | 2022-06-24 |
EP3383495A1 (en) | 2018-10-10 |
KR102444438B1 (ko) | 2022-09-19 |
EP3795147A1 (en) | 2021-03-24 |
JP2018535988A (ja) | 2018-12-06 |
CN108430582A (zh) | 2018-08-21 |
CA3007116A1 (en) | 2017-06-08 |
EP3383495B1 (en) | 2021-01-20 |
CN108430582B (zh) | 2020-02-21 |
US20170159013A1 (en) | 2017-06-08 |
EP3795147B1 (en) | 2023-08-30 |
EP3383495A4 (en) | 2019-09-04 |
US20180148688A1 (en) | 2018-05-31 |
CN111184739A (zh) | 2020-05-22 |
US9885015B2 (en) | 2018-02-06 |
KR20180081824A (ko) | 2018-07-17 |
US10253293B2 (en) | 2019-04-09 |
AU2016364845A1 (en) | 2018-06-21 |
JP6951336B2 (ja) | 2021-10-20 |
KR20200043503A (ko) | 2020-04-27 |
WO2017096123A1 (en) | 2017-06-08 |
AU2016364845B2 (en) | 2022-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1256307A1 (zh) | 用小分子混合物將人神經膠質細胞化學重編程為神經元 | |
HK1232239A1 (zh) | 細胞穿透肽及其製造和使用方法 | |
EP3213054A4 (en) | Determination of water treatment parameters based on absorbance and fluorescence | |
EP3213055A4 (en) | Determination of water treatment parameters based on absorbance and fluorescence | |
EP3145875A4 (en) | Electrochemical treatment methods | |
SG11201606934SA (en) | Improved reprogramming methods and cell culture platforms | |
EP2994530A4 (en) | PROTEIN MODIFICATION OF LIVING CELLS USING SORTASE | |
HK1251623A1 (zh) | T細胞耗盡或缺乏t細胞共刺激的檢測及其用途 | |
EP3331988A4 (en) | CHEMICAL REPROGRAMMING FOR GENERATING NEURONAL CELLS | |
EP3095865A4 (en) | Molecule associated with onset of gout, and method and kit for evaluating diathesis of uric acid-related diseases and inflammation-related diseases, and inspection object and drug | |
ZA201704793B (en) | Treatment of retinal degeneration using progenitor cells | |
EP3157504A4 (en) | Stem cell stimulating compositions and methods | |
EP2956086A4 (en) | ELECTROCHEMICAL MATERIAL PROCESSING, PROCESSES AND PRODUCTION | |
EP3485927C0 (en) | BLOOD SAMPLE TREATMENT USING OPEN PORE FOAM | |
HK1254588A1 (zh) | 間充質幹細胞用於治療骨關節炎的用途 | |
HK1250329A1 (zh) | 使用祖細胞治療眼部病症 | |
EP3122895A4 (en) | Self aligned and scalable nanogap post processing for dna sequencing | |
IL281185A (en) | Treatment of diabetic peripheral neuropathy using placental cells | |
GB2539857B (en) | Devices and methods for purification, detection and use of biological cells | |
IL267231A (en) | Methods of treating diseases associated with ilc2 cells | |
GB201418980D0 (en) | Cell assay kit and method | |
IL262951A (en) | Methods of drug therapy associated with ilc3 cells | |
ZA201607693B (en) | Selective analysis of modified biological molecules with solid-state nanopores | |
AU2015903963A0 (en) | Water Treatment Chemical Composition and Process | |
AU2014901577A0 (en) | Thermo-Electrochemical Cell and Method of Use |